First 3D-printed pill approved by US authorities
In a world first, the US Food and Drug Administration has given the go-ahead for a 3D-printed pill to be produced.
The FDA has previously approved medical devices - including prosthetics - that have been 3D printed.
The new drug, dubbed Spritam, was developed by Aprecia Pharmaceuticals to control seizures brought on by epilepsy.
The company said that it planned to develop other medications using its 3D platform.
Printing the drugs allows layers of medication to be packaged more tightly in precise dosages.
A separate technology developed by the firm, known as ZipDose, makes high-dose medications easier to swallow.
Printing the drug meant it could package up to 1,000 milligrams into individual tablets.
The 3D-printed pill dissolves in the same manner as other oral medicines.
Being able to 3D print a tablet offers the potential to create bespoke drugs based on the specific needs of patients, rather than having a one product fits all approach, according to experts.
"For the last 50 years we have manufactured tablets in factories and shipped them to hospitals and for the first time this process means we can produce tablets much closer to the patient," said Dr Mohamed Albed Alhnan, a lecturer in pharmaceutics at the University of Central Lancashire.
It would mean that medical institutions could adjust the dose for individual patients with just a simple tweak to the software before printing. Previously, such personalised medicine would have been extremely expensive to produce, said Dr Alhnan.
3D printing works by creating an object layer by layer. In the case of medicines, printers are adapted to produce pharmaceutical compounds rather than polymers which are more usually used.
Such methods are already proving very useful in healthcare with doctors using the system to create customised implants for patients with injuries or other conditions.
And dentists, for example, use 3D printers to create replica jaws and teeth as well as other dental implants.
Spritam will launch in the first quarter of 2016, according to Aprecia.